Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors.
Humans with congenital absence of the islets of Langerhans and mice rendered null for the insulin receptor rapidly develop severe hyperglycemia and ketoacidosis and, if untreated, die in the early neonatal period. In contrast, children with homozygous or compound heterozygous mutations of the insulin receptor gene, although hyperglycemic postprandially, survive for many months without developing ketoacidosis. Paradoxically, they often develop hypoglycemia. The rarity of the condition and the difficulties of undertaking metabolic studies in ill infants have limited the physiological information that might explain the clinical features. We studied a boy with Donohue's syndrome who represents a further example of the null phenotype, with two different and novel nonsense mutations in the alpha-subunit of the receptor. He survived for 8 months without developing ketoacidosis, and fasting hypoglycemia was a frequent problem. Despite the complete absence of insulin receptors, evidence for persistent insulin-like effects on fat and liver was seen; fasting plasma beta-hydroxybutyrate and nonesterified fatty acid levels were low, fell further during the early postprandial period, and failed to rise in response to hypoglycemia. The inverse relationships between plasma insulin and insulin-like growth factor-binding protein-1 levels were maintained, suggesting persistent hepatic effects of insulin. GH levels measured over a 6.5-h period were low throughout. Thus, the differences between congenital insulin deficiency vs. insulin receptor deficiency in humans may be explained by persistent insulinomimetic activity of the grossly elevated plasma insulin presumably being mediated through the type 1 insulin-like growth factor receptor. As GH plays a critical role in the regulation of ketogenesis during insulinopenia in humans, but not in rodents, this may contribute to the distinct phenotype of human vs. mouse insulin receptor knockouts.
Ogilvy-Stuart
A L
AL
Department of Pediatrics, Addenbrooke's Hospital, Cambridge, United Kingdom CB2 2QQ. amanda.ogilvy-stuart@addenbrookes.nhs.uk
Soos
M A
MA
Hands
S J
SJ
Anthony
M Y
MY
Dunger
D B
DB
O'Rahilly
S
S
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000273:Adipose Tissue / Q000187:drug effects; D002461:Cell Line, Transformed; D018389:Codon, Nonsense; D016883:Diabetic Ketoacidosis; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005951:Glucose Tolerance Test; D004854:Herpesvirus 4, Human; D006801:Humans; D007003:Hypoglycemia / Q000235:genetics*; D007223:Infant; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007335:Insulin-Like Growth Factor II / Q000032:analysis; D007662:Ketosis / Q000235:genetics*; D008099:Liver / Q000187:drug effects; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D011972:Receptor, Insulin / Q000172:deficiency* / Q000235:genetics*
D018389:Codon, Nonsense; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1; D018972:Insulin-Like Growth Factor Binding Protein 3; D007335:Insulin-Like Growth Factor II; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin; D020155:3-Hydroxybutyric Acid